These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38879876)

  • 21. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
    Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
    Front Immunol; 2020; 11():620098. PubMed ID: 33658996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Off-label Studies on the Use of Ruxolitinib in Dermatology.
    Tegtmeyer K; Ravi M; Zhao J; Maloney NJ; Lio PA
    Dermatitis; 2021 May-Jun 01; 32(3):164-172. PubMed ID: 33443378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JAK inhibitors for the treatment of vitiligo.
    Inoue S; Suzuki T; Sano S; Katayama I
    J Dermatol Sci; 2024 Mar; 113(3):86-92. PubMed ID: 38326166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis.
    Krajewski PK; Szepietowski JC
    Expert Rev Clin Immunol; 2023 Apr; 19(4):349-356. PubMed ID: 36542765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
    Craiglow BG; King BA
    JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
    Vaddi K; Sarlis NJ; Gupta V
    Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.
    Kim BS; Howell MD; Sun K; Papp K; Nasir A; Kuligowski ME;
    J Allergy Clin Immunol; 2020 Feb; 145(2):572-582. PubMed ID: 31629805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial.
    Niezgoda A; Winnicki A; Kosmalski T; Kowaliszyn B; Krysiński J; Czajkowski R
    Trials; 2019 Jan; 20(1):78. PubMed ID: 30683146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature.
    Relke N; Gooderham M
    J Cutan Med Surg; 2019; 23(3):298-306. PubMed ID: 30902022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence.
    Sardana K; Muddebihal A; Khurana A
    Expert Rev Clin Pharmacol; 2023; 16(12):1221-1227. PubMed ID: 37982238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Off-label studies on ruxolitinib in dermatology: a review.
    Wu J; Smogorzewski J
    J Dermatolog Treat; 2022 Mar; 33(2):606-612. PubMed ID: 32515635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utilization of Topical Ruxolitinib in Dermatology: A Review.
    Kashetsky N; Turchin I
    Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
    Qi F; Liu F; Gao L
    Front Immunol; 2021; 12():790125. PubMed ID: 34868078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Concepts of Treatment for Patients with Myelofibrosis.
    Bose P; Alfayez M; Verstovsek S
    Curr Treat Options Oncol; 2019 Jan; 20(1):5. PubMed ID: 30675650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ruxolitinib cream (Opzelura) for nonsegmental vitiligo.
    Med Lett Drugs Ther; 2022 Oct; 64(1660):158-159. PubMed ID: 36206166
    [No Abstract]   [Full Text] [Related]  

  • 37. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
    Huang MY; Armstrong AW
    Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata.
    Tembunde Y; Kindred C
    J Drugs Dermatol; 2024 May; 23(5):378-379. PubMed ID: 38709705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review.
    Dogra S; Sharma A; Mehta H; Sarkar R
    Clin Exp Dermatol; 2023 Sep; 48(10):1102-1112. PubMed ID: 37235767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.